QUEBEC CITY, Dec. 10 /CNW Telbec/ - Victhom Human Bionics Inc. (Victhom,
TSX: VHB) announced today that it has received the authorization from the
Canadian health authorities to begin the clinical investigation of the
Neurostep(TM) at Hôpital de l'Enfant-Jésus in Quebec City.
Mr. Nader Kameli, COO, Neurobionix business unit, said: "We are very
proud to open a second Canadian site in Quebec City, where the Company has its
headquarters. This product is the result of the hard work and dedication of
Victhom employees. The success of this trial would help bring the innovation
of Neurostep(TM) to foot-drop patients around the globe." He added that with
the previously announced sites in Vancouver and the U.K., Victhom is now
working with three sites. He reiterated the importance of this clinical trial
for the Neurostep(TM) and added that these results should provide to Victhom a
solid proof of concept on the Closed-Loop System and the Neurocuff(TM), which
could lead to the development of new exciting indications.
"We are glad to see that a technological breakthrough aims to improve the
quality of life of people with neurological disorders such as foot drop. We
are also proud to collaborate with this development with a Quebec company,
underlining Quebec's know-how in the field of neurological sciences and
biomedical engineering," stated Dr. Michel Prud'Homme, neurosurgeon at Hôpital
de l'Enfant-Jésus and professor at Université Laval in Quebec City.
The Neurostep(TM) is the first fully implantable product designed to
treat, through neuromodulation, gait disorders (e.g., foot drop) which can
result from a lesion of the central nervous system caused by conditions such
as stroke and multiple sclerosis. There are more than 1,400,000 new cases of
stroke per year worldwide and approximately 20 to 30% of these patients will
develop symptoms of foot drop. The Closed-Loop System of the Neurostep(TM)
allows the combination of the sensing and stimulating features to widen the
scope of therapeutic possibilities as compared to conventional technologies
that use stimulation only.
Victhom discovers, develops and manufactures bionic devices involved in
the treatment of a variety of physical and physiological dysfunctions.
Victhom's Neurobionix business unit focuses on the development and
commercialization of technologies and products involving implantable devices
that feature neurosensing and neurostimulation components, integrated with
artificial intelligence. Victhom's Biotronix business unit develops
biomechatronic products to support or replace peripheral limbs in what is
known as the orthotics and prosthetics market.
Some of the statements made herein may constitute forward-looking
statements. These statements relate to future events or our future financial
performance and involve known and unknown risks, uncertainties and other
factors that may cause Victhom's actual results, performance or achievements
to be materially different from those expressed or implied by any of Victhom's
statements. Actual events or results may differ materially. We disclaim any
intention, and assume no obligation, to update these forward-looking
For further information:
For further information: Mr. Benoit Huet, President & CEO, Victhom Human
Bionics, (418) 872-5665, Fax: (418) 872-6926, email@example.com;
www.victhom.com; Source: Victhom Human Bionics Inc.